Structure Announces Positive Topline Results from Ph1b Oral GLP-1RA Study; Better Therapeutics Completes Enrollment of AspyreRX Clinical Program in T2DM; Madrigal Commences $500M Public Offering

Three cardiometabolic-related news items have been observed: Structure Therapeutics announced positive topline results from its Ph1b MAD study evaluating QD doses of GSBR-1290, its oral GLP-1RA, in healthy overweight or obese individuals and provided updates regarding its GSBR-1290 development program (view press release); Better Therapeutics announced it completed enrollment of the AspyreRx clinical program to provide cognitive behavioral therapy for adults with T2DM (view press release); and Madrigal announced it commenced its $500M public offering in shares of its common stock and pre-funded warrants (view press release). Below, FENIX provides highlights and insights into the respective items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.